المصدر: Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05511844Test

المؤلفون: Odense University Hospital, Aalborg University Hospital, Aarhus University Hospital

المساهمون: Morten Mau-Sørensen, MD PhD

المصدر: HERES Trial: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05170256Test

المصدر: Klhsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmrer M, Gabruswz K, Anderson NR, Petty NE, Cumms KD, Shen F, Shan X, Vel K, Blouch K, Yasho-OhtanY, Kendern SS, K MY, O'Connor RS, Wallace SR, KozlowskMS, Marchne DM, Shestov M, Garc BA, June CH, Gl S. Human cher anten receptor macrophages for cancer munotherapy. Nat Btechnol. 2020 Aug;38(8):947-953. do 10.1038/s41587-020-0462-y. Epub 2020 Mar 23.
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04660929Test

المصدر: A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04650451Test

المؤلفون: Asan Medical Center

المساهمون: Jin-Hee Ahn, Clinical Professor

المصدر: Prospective Phase II Study to Investigate the Efficacy and Safety of Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Solid Tumor

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04215159Test

المؤلفون: Jiangsu HengRui Medicine Co., Ltd.

المصدر: An Open-label, Phase 2 Study of Pyrotinib Maleate in Advanced Solid Tumors Patients With HER2( Erb-B2 Receptor Tyrosine Kinase 2)-Postive

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04179656Test

المصدر: Immune Response Surveillance and Potential Booster Vaccines for Patients Who Have Received HER2-pulsed DC1 Vaccine

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03630809Test

المساهمون: Changhoon Yoo, Assistant professor

المصدر: The Pilot Study of Trastuzumab in Combination With Gemcitabine Plus Cisplatin for HER2-positive Biliary Tract Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03613168Test